



# Louisiana

## Allogeneic Pancreas Transplant

**Policy #** 00092

**Original Effective Date:** 11/22/1993

**Current Effective Date:** 02/08/2021

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

*Note: Islet cell transplantation is considered in medical policy 00007.*

### When Services May Be Eligible for Coverage

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider a combined pancreas-kidney transplant in insulin dependent diabetic patients with uremia to be **eligible for coverage.\*\***

Based on review of available data, the Company may consider pancreas transplant after a prior kidney transplant in patients with insulin dependent diabetes to be **eligible for coverage.\*\***

Based on review of available data, the Company may consider pancreas transplant alone in patients with severely disabling and potentially life-threatening complications due to hypoglycemia unawareness and labile insulin dependent diabetes that persists in spite of optimal medical management to be **eligible for coverage.\*\***

Based on review of available data, the Company may consider pancreas retransplant after a failed primary pancreas transplant in patients who meet criteria for pancreas transplantation to be **eligible for coverage.\*\***

Pancreas transplantation, when the transplant recipient is human immunodeficiency virus (HIV) positive, may be considered for coverage when all of the additional criteria are met:

- CD4 count >200 cells/mm<sup>3</sup> for more than six months; and
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least six months; and
- Demonstrable adherence and a stable HAART regimen for at least six months; and

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

- Absence of AIDS-defining illness following successful immune reconstitution after HAART; and
- All other transplant criteria are met.

### **When Services Are Considered Investigational**

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

The use of pancreas transplant when patient selection criteria are not met is considered **investigational**.\*

The use of pancreas transplant in HIV positive recipients when patient selection criteria and additional HIV positive patient selection criteria are not met is considered **investigational**.\*

Based on review of available data, pancreas re-transplantation after two or more prior failed pancreas transplants is considered **investigational**.\*

## **Policy Guidelines**

### **General Criteria**

Potential contraindications for solid organ transplant are subject to the judgment of the transplant center include the following:

1. Known current malignancy, including metastatic cancer
2. Recent malignancy with high-risk of recurrence
3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
4. Other irreversible end-stage diseases not attributed to kidney disease
5. History of cancer with a moderate risk of recurrence
6. Systemic disease that could be exacerbated by immunosuppression
7. Psychosocial conditions or chemical dependency affecting the ability to adhere to therapy.

### **Pancreas-Specific Criteria**

Candidates for pancreas transplant alone should also meet one of the following severity of illness criteria:

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

- Documentation of severe hypoglycemia unawareness as evidenced by chart notes or emergency department visits or
- Documentation of potentially life-threatening labile diabetes, as evidenced by chart notes or hospitalization for diabetic ketoacidosis.

Additionally, most pancreas transplant patients will have type 1 diabetes. Those transplant candidates with type 2 diabetes, in addition to being insulin-dependent, should also not be obese (body mass index should be  $\leq 32$  kg/m<sup>2</sup>). According to International Pancreas Transplant Registry data, in 2010, 7% of pancreas transplant recipients had type 2 diabetes (Gruessner [2011]).

### **Multiple Transplant Criteria**

Although there are no standard guidelines for multiple pancreas transplants, the following information may aid in case review:

- If there is early graft loss resulting from technical factors (eg, venous thrombosis), a retransplant may generally be performed without substantial additional risk.
- Long-term graft losses may result from chronic rejection, which is associated with increased risk of infection following long-term immunosuppression, and sensitization, which increases the difficulty of finding a negative cross-match. Some transplant centers may wait to allow reconstitution of the immune system before initiating retransplant with an augmented immunosuppression protocol.

## **Background/Overview**

Solid organ transplantation offers a treatment option for patients with different types of end-stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life. Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

### **Allogeneic Pancreas Transplant**

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

In 2019, 39,719 transplants were performed in the United States procured from almost 11,900 deceased donors and 7,400 living donors. Pancreas-kidney transplants were the fifth most common procedure, with 872 transplants performed in 2019. Pancreas-alone transplants were the sixth most common procedure, with 143 transplants performed in 2019.

Pancreas transplantation occurs in several different scenarios such as (1) a diabetic patient with renal failure who may receive a simultaneous cadaveric pancreas plus kidney transplant; (2) a diabetic patient who may receive a cadaveric or living-related pancreas transplant after a kidney transplantation (pancreas after kidney); or (3) a nonuremic diabetic patient with specific severely disabling and potentially life-threatening diabetic problems who may receive a pancreas transplant alone.

Data from the United Network for Organ Sharing and the International Pancreas Transplant Registry indicate that the proportion of simultaneous pancreas plus kidney transplant recipients worldwide who have type 2 diabetes has increased over time, from 6% of transplants between 2005 and 2009 to 9% of transplants between 2010 and 2014. Between 2010 and 2014, approximately 4% of pancreas after kidney transplants and 4% of pancreas alone transplants were performed in patients with type 2 diabetes. In 2018, patients with type 2 diabetes accounted for 14.8% of all pancreas transplants, according to data from the Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Patients with type 2 diabetes accounted for 1.1%, 10.3%, and 16.7% of pancreas alone, pancreas after kidney, and simultaneous pancreas plus kidney transplants, respectively.

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

Solid organ transplants are a surgical procedure and, as such, are not subject to regulation by the U.S. FDA.

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Solid organs used for transplantation are subject to these regulations.

## **Rationale/Source**

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

Transplantation of a healthy pancreas is a treatment for patients with insulin-dependent diabetes. Pancreas transplantation can restore glucose control and prevent, halt, or reverse the secondary complications from diabetes.

For individuals who have insulin-dependent diabetes who receive a pancreas transplant after a kidney transplant, the evidence includes retrospective studies and registry studies. Relevant outcomes are overall survival (OS), change in disease status, and treatment-related mortality and morbidity. Data from national and international registries have found relatively high patient survival rates with a pancreas transplant after a kidney transplant (eg, a 3-year survival rate of 94.5%). Single-center retrospective studies have found similar patient survival and death-censored pancreas graft survival rates with a pancreas transplant after a kidney transplant or a simultaneous pancreas and kidney (SPK) transplant. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have insulin-dependent diabetes with uremia who receive SPK transplants, the evidence includes retrospective studies and registry studies. Relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Data from national and international registries have found relatively high patient survival rates after SPK transplant. A retrospective analysis found a higher survival rate in patients with type 1 diabetes who had an SPK transplant versus those on a waiting list. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have insulin-dependent diabetes and severe complications who receive pancreas transplant alone, the evidence includes registry studies. Relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Data from international and national registries have found that graft and patient survival rates after pancreas transplant alone have improved over time (eg, 3-year survival of 94.9%). The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have had a prior pancreas transplant who still meet criteria for a pancreas transplant who receive pancreas retransplantation, the evidence includes retrospective studies and registry studies. Relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. National data and specific transplant center data have generally found similar graft and patient survival rates after pancreas retransplantation compared with initial transplantation. The

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## **Supplemental Information**

### **Practice Guidelines and Position Statements**

#### **Organ Procurement and Transplantation Network**

The Organ Procurement and Transplantation Network updated its comprehensive list of transplant-related policies, most recently in June 2020.

For pancreas registration:

"Each candidate registered on the pancreas waiting list must meet *one* of the following requirements:

- Be diagnosed with diabetes
- Have pancreatic exocrine insufficiency
- Require the procurement or transplantation of a pancreas as part of a multiple organ transplant for technical reasons."

For combined kidney plus pancreas registration: "Each candidate registered on the kidney-pancreas waiting list must be diagnosed with diabetes or have pancreatic exocrine insufficiency with renal insufficiency."

#### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

#### **Medicare National Coverage**

An allogeneic pancreas transplant is covered under Medicare when performed in a facility approved by Medicare as meeting institutional coverage criteria<sup>31</sup>. The Centers for Medicare & Medicaid Services made the following national coverage decision on pancreas transplant for Medicare recipients.

"A. General

Pancreas transplantation is performed to induce an insulin-independent, euglycemic state in diabetic patients. The procedure is generally limited to those patients with severe secondary

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

complications of diabetes, including kidney failure. However, pancreas transplantation is sometimes performed on patients with labile diabetes and hypoglycemic unawareness.

### B. Nationally Covered Indications

Effective ... 1999, whole organ pancreas transplantation is nationally covered by Medicare when performed simultaneously with or after a kidney transplant. If the pancreas transplant occurs after the kidney transplant, immunosuppressive therapy begins with the date of discharge from the inpatient stay for the pancreas transplant.

Effective ... 2006, pancreas transplants alone (PA) are reasonable and necessary for Medicare beneficiaries in the following limited circumstances:

1. PA will be limited to those facilities that are Medicare-approved for kidney transplantation.
2. Patients must have a diagnosis of type I diabetes:
  - Patient with diabetes must be beta-cell autoantibody-positive; or
  - Patient must demonstrate insulinopenia defined as a fasting C-peptide level that is less than or equal to 110% of the lower limit of normal of the laboratory's measurement method. Fasting C-peptide levels will only be considered valid with a concurrently obtained fasting glucose  $\leq 225$  mg/dL;
3. Patients must have a history of medically-uncontrollable labile (brittle) insulin-dependent diabetes mellitus with documented recurrent, severe, acutely life-threatening metabolic complications that require hospitalization. Aforementioned complications include frequent hypoglycemia unawareness or recurring severe ketoacidosis, or recurring severe hypoglycemic attacks;
4. Patients must have been optimally and intensively managed by an endocrinologist for at least 12 months with the most medically recognized advanced insulin formulations and delivery systems;
5. Patients must have the emotional and mental capacity to understand the significant risks associated with surgery and to effectively manage the lifelong need for immunosuppression; and,
6. Patients must otherwise be a suitable candidate for transplantation."

Nationally noncovered indications include "Transplantation of partial pancreatic tissue or islet cells (except in the context of a clinical trial)."

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

### Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

**Table 1. Summary of Key Trials**

| NCT No.            | Trial Name                                                   | Planned Enrollment | Completion Date |
|--------------------|--------------------------------------------------------------|--------------------|-----------------|
| <i>Ongoing</i>     |                                                              |                    |                 |
| NCT01047865        | Type 1 Diabetes Recurrence in Pancreas Transplants           | 400                | May 2022        |
| NCT01957696        | The Norwegian Pancreas Transplantation (PTx) Study (PTx)     | 80                 | Oct 2028        |
| <i>Unpublished</i> |                                                              |                    |                 |
| NCT00238693        | Transplant Patient Registry of Liver, Kidney and/or Pancreas | 13,767             | Aug 2018        |

NCT: national clinical trial.

## References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Allogeneic Pancreas Transplant”, 7.03.02, 9:2020.
2. Kandaswamy R, Stock PG, Gustafson SK, et al. OPTN/SRTR 2018 Annual Data Report: Pancreas. Am J Transplant. Jan 2020; 20 Suppl s1: 131-192. PMID 31898415
3. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. Ann Transl Med. Oct 2018; 6(20): 409. PMID 30498736
4. United Network for Organ Sharing (UNOS). Transplant trends. 2020; <https://unos.org/data/transplant-trends/>.
5. Gruessner AC, Gruessner RW. Pancreas Transplantation of US and Non-US Cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2016; 13(1): 35-58. PMID 26982345

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Pancreas Transplantation. TEC Assessments. 1998;Volume 13, Tab 7.
7. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Pancreas Retransplantation. TEC Assessments. 2001;Volume 16, Tab 23.
8. Parajuli S, Arunachalam A, Swanson KJ, et al. Outcomes after simultaneous kidney-pancreas versus pancreas after kidney transplantation in the current era. *Clin Transplant*. Dec 2019; 33(12): e13732. PMID 31628870
9. Bazerbachi F, Selzner M, Marquez MA, et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. *Transplantation*. Feb 15 2013; 95(3): 489-94. PMID 23183776
10. Fridell JA, Mangus RS, Hollinger EF, et al. The case for pancreas after kidney transplantation. *Clin Transplant*. Aug-Sep 2009; 23(4): 447-53. PMID 19453642
11. Kleinclauss F, Fauda M, Sutherland DE, et al. Pancreas after living donor kidney transplants in diabetic patients: impact on long-term kidney graft function. *Clin Transplant*. Aug-Sep 2009; 23(4): 437-46. PMID 19496790
12. Organ Procurement and Transplantation Network (OPTN). National Data. n.d.; <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>.
13. Barlow AD, Saeb-Parsy K, Watson CJE. An analysis of the survival outcomes of simultaneous pancreas and kidney transplantation compared to live donor kidney transplantation in patients with type 1 diabetes: a UK Transplant Registry study. *Transpl Int*. Sep 2017; 30(9): 884-892. PMID 28319322
14. van Dellen D, Worthington J, Mitu-Pretorian OM, et al. Mortality in diabetes: pancreas transplantation is associated with significant survival benefit. *Nephrol Dial Transplant*. May 2013; 28(5): 1315-22. PMID 23512107
15. Sampaio MS, Kuo HT, Bunnapradist S. Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. *Clin J Am Soc Nephrol*. May 2011; 6(5): 1198-206. PMID 21441123
16. Pugliese A, Reijonen HK, Nepom J, et al. Recurrence of autoimmunity in pancreas transplant patients: research update. *Diabetes Manag (Lond)*. Mar 2011; 1(2): 229-238. PMID 21927622
17. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). *Rev Diabet Stud*. 2011; 8(1): 6-16. PMID 21720668

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

18. Scalea JR, Butler CC, Munivenkatappa RB, et al. Pancreas transplant alone as an independent risk factor for the development of renal failure: a retrospective study. *Transplantation*. Dec 27 2008; 86(12): 1789-94. PMID 19104423
19. Parajuli S, Arunachalam A, Swanson KJ, et al. Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival. *Transplant Direct*. Aug 2019; 5(8): e473. PMID 31576369
20. Gasteiger S, Cardini B, Gobel G, et al. Outcomes of pancreas retransplantation in patients with pancreas graft failure. *Br J Surg*. Dec 2018; 105(13): 1816-1824. PMID 30007018
21. Buron F, Thaunat O, Demuylder-Mischler S, et al. Pancreas retransplantation: a second chance for diabetic patients?. *Transplantation*. Jan 27 2013; 95(2): 347-52. PMID 23222920
22. Fridell JA, Mangus RS, Chen JM, et al. Late pancreas retransplantation. *Clin Transplant*. Jan 2015; 29(1): 1-8. PMID 25284041
23. Seal J, Selzner M, Laurence J, et al. Outcomes of pancreas retransplantation after simultaneous kidney-pancreas transplantation are comparable to pancreas after kidney transplantation alone. *Transplantation*. Mar 2015; 99(3): 623-8. PMID 25148379
24. Rudolph EN, Finger EB, Chandolias N, et al. Outcomes of pancreas retransplantation. *Transplantation*. Feb 2015; 99(2): 367-74. PMID 25594555
25. Organ Procurement and Transplantation Network (OPTN). OPTN Policies. 2020; [https://optn.transplant.hrsa.gov/media/1200/optn\\_policies.pdf](https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf).
26. Blumberg EA, Rogers CC. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. Sep 2019; 33(9): e13499. PMID 30773688
27. Siskind E, Maloney C, Akerman M, et al. An analysis of pancreas transplantation outcomes based on age groupings--an update of the UNOS database. *Clin Transplant*. Sep 2014; 28(9): 990-4. PMID 24954160
28. Shah AP, Mangus RS, Powelson JA, et al. Impact of recipient age on whole organ pancreas transplantation. *Clin Transplant*. Jan-Feb 2013; 27(1): E49-55. PMID 23228216
29. Afaneh C, Rich BS, Aull MJ, et al. Pancreas transplantation: does age increase morbidity?. *J Transplant*. 2011; 2011: 596801. PMID 21766007
30. Schenker P, Vonend O, Kruger B, et al. Long-term results of pancreas transplantation in patients older than 50 years. *Transpl Int*. Feb 2011; 24(2): 136-42. PMID 21039944
31. Gruessner AC, Sutherland DE. Access to pancreas transplantation should not be restricted because of age: invited commentary on Schenker et al. *Transpl Int*. Feb 2011; 24(2): 134-5. PMID 21208293

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

32. Centers for Medicare & Medicaid Services (CMS). Transplant. 2020; <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandCompliance/Transplant>.
33. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Pancreas Transplants (260.3). 2006; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=107&ver=3>.

### **Policy History**

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

- |            |                                                                                                                                                           |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/21/2001 | Managed Care Advisory Council approval                                                                                                                    |
| 11/18/2003 | Medical Policy Committee review                                                                                                                           |
| 01/26/2004 | Managed Care Advisory Council approval                                                                                                                    |
| 01/04/2005 | Medical Director review                                                                                                                                   |
| 01/18/2005 | Medical Policy Committee review. Format revision. No substance change to policy.                                                                          |
| 01/31/2005 | Managed Care Advisory Council approval                                                                                                                    |
| 02/01/2006 | Medical Director review                                                                                                                                   |
| 03/15/2006 | Medical Policy Committee approval. Format revision.                                                                                                       |
| 02/07/2007 | Medical Director review                                                                                                                                   |
| 02/21/2007 | Medical Policy Committee approval. Coverage eligibility unchanged.                                                                                        |
| 02/13/2008 | Medical Director review                                                                                                                                   |
| 02/20/2008 | Medical Policy Committee approval.                                                                                                                        |
| 02/04/2009 | Medical Director review                                                                                                                                   |
| 02/19/2009 | Medical Policy Committee approval. Clarified 2nd, 3rd and 4th criteria bullets for HIV positive transplant recipients. No change to coverage eligibility. |
| 02/04/2010 | Medical Policy Committee approval                                                                                                                         |
| 02/17/2010 | Medical Policy Implementation Committee approval. No change to coverage.                                                                                  |
| 02/03/2011 | Medical Policy Committee approval                                                                                                                         |
| 02/16/2011 | Medical Policy Implementation Committee approval. No change to coverage.                                                                                  |
| 02/02/2012 | Medical Policy Committee approval                                                                                                                         |
| 02/15/2012 | Medical Policy Implementation Committee approval. Patient selection criteria revised.                                                                     |
| 01/03/2013 | Medical Policy Committee approval                                                                                                                         |

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

01/09/2013 Medical Policy Implementation Committee approval. No change to coverage.  
01/09/2014 Medical Policy Committee approval  
01/15/2014 Medical Policy Implementation Committee approval. Patient selection criteria section removed.  
01/08/2015 Medical Policy Committee approval  
01/21/2015 Medical Policy Implementation Committee approval. Added “in patients who meet criteria for pancreas transplantation” in the criteria for pancreas retransplant after a failed primary pancreas transplant.  
01/07/2016 Medical Policy Committee approval  
01/22/2016 Medical Policy Implementation Committee approval. No change to coverage.  
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes  
01/05/2017 Medical Policy Committee approval  
01/18/2017 Medical Policy Implementation Committee approval. No change to coverage  
01/04/2018 Medical Policy Committee approval  
01/17/2018 Medical Policy Implementation Committee approval. No change to coverage. Added policy guidelines.  
01/10/2019 Medical Policy Committee approval  
01/23/2019 Medical Policy Implementation Committee approval. No change to coverage  
01/03/2020 Medical Policy Committee review  
01/08/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.  
01/07/2021 Medical Policy Committee review  
01/13/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 01/2022

### **Coding**

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

*The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.*

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

| Code Type        | Code                              |
|------------------|-----------------------------------|
| CPT              | 48550, 48551, 48552, 48554, 48556 |
| HCPCS            | S2065, S2152                      |
| ICD-10 Diagnosis | All related diagnoses             |

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Allogeneic Pancreas Transplant

Policy # 00092

Original Effective Date: 11/22/1993

Current Effective Date: 02/08/2021

diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**\*\*Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.